Falkenius, J., Johansson, H., Tuominen, R., Frostvik Stolt, M., Hansson, J., & Egyhazi Brage, S. (2017). Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma. BMC Cancer.

Falkenius, Johan, Hemming Johansson, Rainer Tuominen, Marianne Frostvik Stolt, Johan Hansson, and Suzanne Egyhazi Brage. "Presence of Immune Cells, Low Tumor Proliferation and Wild Type BRAF Mutation Status Is Associated With a Favourable Clinical Outcome in Stage III Cutaneous Melanoma." BMC Cancer 2017.

Falkenius, Johan, et al. "Presence of Immune Cells, Low Tumor Proliferation and Wild Type BRAF Mutation Status Is Associated With a Favourable Clinical Outcome in Stage III Cutaneous Melanoma." BMC Cancer 2017.